TNF superfamily member 13Genealiases: APRIL · CD256 · TALL-2 · TALL2 · TNLG7B · TRDL-1
Q-omics provides the consensus-scored TNFSF13 profile across patient tissues and cancer cell-line models. TNFSF13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TNFSF13 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TNFSF13 RNA expression shows 21,553 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, COAD, and LSCC as cancer lineages where TNFSF13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFSF13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFSF13 survival associations across molecular data types. TNFSF13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFSF13 RNA expression–survival associations across cancer types. High TNFSF13 expression shows unfavorable associations in LGG, but favorable associations in MESO, KIRC, UVM, HNSC and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TNFSF13 RNA expression.
This table summarizes TNFSF13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TNFSF13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFSF13 shows lower tumor expression in COAD, KICH, LUSC, LUAD and READ and higher tumor expression in CHOL. The COAD box plot shows higher TNFSF13 RNA expression in normal versus tumor tissue (log2 FC = −1.440, t-test p < 0.001).
This table shows molecular features associated with TNFSF13 in patient tissues and cancer cell lines. In patient samples, TNFSF13 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFSF13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
